Related Experiment Video
Updated: Jun 25, 2025

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
Sequencing-guided design of genetically encoded small RNAs targeting CAG repeats for selective inhibition of mutant
Mansi A Parasrampuria1, Adam A White1, Ramadevi Chilamkurthy1
1Division of Biochemistry and Molecular Biology, Southern Illinois University School of Medicine, Carbondale, IL 62901, USA.
Insights
Researchers developed genetically encoded small RNAs to precisely target mutant huntingtin (HTT) in Huntington's disease (HD). This approach shows promise for allele-selective gene therapy by reducing harmful mutHTT without affecting healthy wtHTT.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Huntington's disease (HD) is a fatal neurodegenerative disorder.
- It is caused by a CAG repeat expansion in the huntingtin (HTT) gene.
- Therapeutic strategies aim to reduce mutant HTT (mutHTT) while preserving wild-type HTT (wtHTT).
Purpose of the Study:
- To evaluate the processing precision of genetically encoded small RNAs targeting the CAG repeat in HD.
- To assess the allele-selective inhibition of mutHTT expression.
- To identify small RNAs with favorable off-target profiles for HD gene therapy.
Main Methods:
- Small RNA sequencing (RNA-seq) was used to analyze the 5' processing precision of CAG repeat-targeted small RNAs.
- Multiple scaffold contexts were tested for small RNA expression.
- Transcriptome-wide mRNA sequencing (mRNA-seq) was employed to evaluate off-target effects.
Main Results:
- Specific expression constructs demonstrated high guide strand 5' processing precision.
- Promising allele-selective inhibition of mutHTT was achieved.
- An allele-selective small RNA with a favorable off-target profile was identified.
Conclusions:
- Genetically encoded repeat-targeted small RNAs are a viable strategy for allele-selective HD gene therapy.
- Sequencing methods are crucial for balancing specificity and allele selectivity in small RNA design.
- Further optimization of these small RNAs is warranted for therapeutic development.
Abstract:
Huntington's disease (HD) is an incurable neurodegenerative disorder caused by genetic expansion of a CAG repeat sequence in one allele of the huntingtin (HTT) gene. Reducing expression of the mutant HTT (mutHTT) protein has remained a clear therapeutic goal, but reduction of wild-type HTT (wtHTT) is undesirable, as it compromises gene function and potential therapeutic efficacy. One promising allele-selective approach involves targeting the CAG repeat expansion with steric binding small RNAs bearing central mismatches. However, successful genetic encoding requires consistent placement of mismatches to the target within the small RNA guide sequence, which involves 5' processing precision by cellular enzymes. Here, we used small RNA sequencing (RNA-seq) to monitor the processing precision of a limited set of CAG repeat-targeted small RNAs expressed from multiple scaffold contexts. Small RNA-seq identified expression constructs with high-guide strand 5' processing precision and promising allele-selective inhibition of mutHTT. Transcriptome-wide mRNA-seq also identified an allele-selective small RNA with a favorable off-target profile. These results support continued investigation and optimization of genetically encoded repeat-targeted small RNAs for allele-selective HD gene therapy and underscore the value of sequencing methods to balance specificity with allele selectivity during the design and selection process.
Related Concept Videos
Experimental RNAi
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

